Activity of Cefiderocol and Comparators against Isolates from Cancer Patients.
Activity of Cefiderocol and Comparators against Isolates from Cancer Patients.
Antimicrob Agents Chemother. 2020 Feb 18;:
Authors: Rolston KVI, Gerges B, Shelburne S, Aitken SL, Raad I, Prince RA
Abstract
Cefiderocol inhibited 97.5% of 478 Gram-negative isolates from cancer patients at ≤ 4 mg/L. It had potent activity against ESBL positive Enterobacteriaceae, carbapenem resistant Enterobacteriaceae, and non-fermenting Gram-negative bacilli including Pseudomonas aeruginosa, Stenotrophomonas maltophilia, and Acinetobacter spp. Amikacin, ceftazidime/avibactam and meropenem had appreciable activity against non-CRE Enterobacteriaceae No comparators were active against MDR P. aeruginosa. Only trimethoprim/sulfamethoxazole had appreciable activity against S. maltophilia Overall, cefiderocol was associated with the lowest level of resistance.
PMID: 32071053 [PubMed - as supplied by publisher]
Source: Antimicrobial Agents and Chemotherapy - Category: Microbiology Authors: Rolston KVI, Gerges B, Shelburne S, Aitken SL, Raad I, Prince RA Tags: Antimicrob Agents Chemother Source Type: research
More News: Acinetobacter | Bactrim | Cancer | Cancer & Oncology | Chemotherapy | Microbiology | Sulfamethoxazole | Trimethoprim